SymBio Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYMQY research report →
About the company
SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. It researches, develops, manufactures, and sells new drugs focusing on the areas of oncology, hematology, and autoimmune diseases.
- CEO
- Fuminori Yoshida
- IPO
- 2016
- Employees
- 91
- HQ
- Minato, NI, JP
Price Chart
- Market Cap
- $26.38M
- P/E
- -0.72
- P/S
- 3.32
- P/B
- 22.24
- EV/EBITDA
- -0.59
- Div Yield
- 0.00%
- Gross Margin
- 71.86%
- Op Margin
- -439.49%
- Net Margin
- -458.55%
- ROE
- -424.34%
- ROIC
- -444.00%
- Revenue
- $1.37B · -44.11%
- Net Income
- $-5,007,740,554 · -30.63%
- EPS
- $-99.73 · -18.64%
- Op Income
- $-4,655,968,416
- FCF YoY
- -38.52%
- 52W High
- $1.19
- 52W Low
- $0.56
- 50D MA
- $0.56
- 200D MA
- $0.63
- Beta
- 0.49
- Avg Volume
- 808.752
Get TickerSpark's AI analysis on SYMQY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SYMQY coverage
Recent articles, reports, and earnings notes.
No research on SYMQY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SYMQY report →Similar companies
Peers in the same neighborhood.